

剤の形状・様態、投与対象の状態、疾患の種類、適用部位、細胞微少環境なども臨床上での腫瘍発生可能性の関連要因であるが、これらをすべて包含した上での外挿性を語るのは現時点できわめて困難である。

(13) 造腫瘍試験はどこまで必要か？体性幹細胞由来製品では動物を用いた試験は不要では？製品の(通常の培養期間、倍加時間、継代数を超える培養時)の増殖曲線などから担保することで良いのではないか(培地、培養条件が課題)。多能性幹細胞の場合は製品レベルでは未分化細胞の残存がまず問題だが、これには、とりあえず、未分化細胞特有の遺伝子発現を高感度なPCRで検出する方策や(製品の)通常を超える培養時による細胞増殖評価。次いで動物試験。(iPS細胞等由来特定製品で、ある種の遺伝子発現と分化異常、あるいはカルシテラトーム発現頻度の高さなどの因果関係が明らかでない場合は、当該遺伝子発現を検討するのは意味あるかも知れない)。本格的には次年度の課題。

(14) 関心事項はなるべくある種の結論を得るべく努力し、公表するが、ガイドライン化した方が良い事項(一般的で共通的な事項)とQA、補遺などで解説した方が良い事項がある。後者には個別製品の上乗せ部分に関わる事項

が多い(例示する)。

(15) 非臨床試験における動物モデル製品とモデル動物の効用。本来のヒト製品と異なる製品を製造しなければならない手間と出来た製品の妥当性をいかに担保するかなどの問題がつきまとう。動物モデル製品は有効性試験については一定の妥当性が考えられるが、安全性試験については、どうか？

(16) いわゆる毒性試験よりも一般薬理試験的なものの方が妥当性は高いのでは。

(17) ある課題の解決策にはケースに応じた多様な答えがある。注釈、説明等をつけながら、何らかの形で公表し、認識できるようにする。

C-7 MCP コンセプトの国際発信

本研究は、あらゆる製品に最低限必須・共通の要件や基準・評価技術(ミニマム・コンセンサス・パッケージ：MCP)を提言し、より合理的、効率的、効果的な製品開発を促進し、再生医療実用化の推進に寄与することを目的としている。MCPは、これを共通のプラットフォームとし、これに各製品の特性等を踏まえた技術的要件を選択して上乗せする、という合理的アプローチを可能にする特色を持つ独創的なものであり、諸外国では類をみず、規制面から国際的

優位性を確保するための方策である。その一方で、こうした方策が世界レベルで認知されること、ひいては世界の標準的アプローチになれば、これに勝るものはない。おりしも、2015年2月18-19日に東京において、International Alliance for Biological Standardization, PMDA, JST, NIBIO, WHOにより

“International Regulatory Endeavor towards Sound Development of Human Cell Therapy Products”と題された国際シンポジウムが開催された。本国際会議の運営委員会には、本研究班代表の早川（委員長）の他、研究分担者である青井、梅澤、佐藤、松山、大和が主要メンバーとして参画しており、MCPをメインテーマの一つとして設定した。ここでMCPプラスケース別上乘せ方策のコンセプト及び事例一般（早川堯夫）、規格及び試験方法（早川堯夫・坂本典久）、iPS細胞（青井貴之）、ES細胞・非臨床有効性（梅澤明弘）、非臨床安全性（松山晃文）、造腫瘍性（佐藤陽治）、臨床評価と課題（大和雅之・矢野一男）、GXP（佐藤大作）、生物由来原材料（前田大輔）その他についてそれぞれわが国関係者が講演し、国際発信した。このうち、MCPプラスケース別上乘せ方策のコンセプト及び事例一般（早川堯夫）のスライド1-64を収載する（スライド1-64）。

D. 考察

本年度の研究では、1) あらゆる製品の試験や評価の際に適用すべき共通の一般的留意事項（一般原則）、2)（改正薬事法）及び再生医療安全性確保法下における、細胞・組織を取り扱う上での最低限必須・共通の技術的・倫理的留意事項や技術要件（GTP（Good Cell/Tissue Practice）のMCP）、3) 製品の製造方法と品質（試験・評価・管理）に関するMCP、4) 非臨床安全性試験におけるMCP、5) 非臨床有効性（POC）試験におけるMCPなどを案出した。これらMCPは必要に応じてガイドライン化されるべきものである。しかし、一般原則、GTP、製品の製造方法と品質については具体的なMCP提案が可能と思われるが、非臨床安全性・有効性試験部分では、むしろケース別にどのような対応すべきかを英知を結集して考案しなければならないところが多いと考えられる。

いずれにしても、MCPを共通のプラットフォームとし、次に製品の種類・特性、対象疾患、開発段階を考慮し、既存の網羅的指針等を参考にしつつ、当該ケースに応じて上乘せすべき試験・評価項目を選択するというアプローチを適用すれば、学・産の研究・開発の実施、官での薬事戦略相談などの円滑な進行、再生医療安全性確保法下でのヒト幹臨床研究等の薬機法下での開発への切れ目のない移行、的確な承認審査などが可能となる。その結果、再生医療等製品の品質及び安全性を確保しつつ、合理的、効率的、効果的な製品開発を促進し、再生医療の実用化の推進に寄与することによ

り、厚生労働行政上きわめて大きな意義を持つと期待される。わが国が欧米を上回るスピードで実用化していくためにも研究成果の果たす役割は大きい。

E. 結論

MCP は再生医療等安全性確保法下でのヒト特定細胞加工物の利用から薬機法の下でのヒト細胞加工製品の開発への切れ目のない移行、行政での薬事戦略相談や承認審査などの円滑な進行を可能にする共通のプラットフォームともなる。欧米ではこのようなアプローチは系統化されていない。わが国が今後、わが国のシーズを欧米を上回るスピードで実用化していくためには、系統化されたガイドランスの存在や今回提言するアプローチの活用がきわめて大きな役割を果たすと考えられる。将来的にはこのアプローチが WHO 等に採択され、世界標準の一つとなる可能性も期待される。

F. 健康危険情報

特記事項なし

G. 研究発表

G-1 論文発表

1) Takao Hayakawa, Takashi Aoi, Akihiro Umezawa, Keiya Ozawa, Yoji Sato, Yoshiki Sawa, Akifumi Matsuyama, Shinya Yamanaka, and Masayuki Yamato. Study on Ensuring the Quality and Safety of Pharmaceuticals and Medical

Devices Derived from the Processing of Autologous Human Somatic Stem Cells. Regenerative Therapy 2015 in press.

2) Takao Hayakawa, Takashi Aoi, Akihiro Umezawa, Keiya Ozawa, Yoji Sato, Yoshiki Sawa, Akifumi Matsuyama, Shinya Yamanaka, and Masayuki Yamato. Study on Ensuring the Quality and Safety of Pharmaceuticals and Medical Devices Derived from the Processing of Allogenic Human Somatic Stem Cells. Regenerative Therapy 2015 in press.

3) Takao Hayakawa, Takashi Aoi, Akihiro Umezawa, Keiya Ozawa, Yoji Sato, Yoshiki Sawa, Akifumi Matsuyama, Shinya Yamanaka, and Masayuki Yamato. Study on Ensuring the Quality and Safety of Pharmaceuticals and Medical Devices Derived from Processing of Autologous Human Induced Pluripotent Stem Cell (-Like Cells). Regenerative Therapy 2015 in press.

4) Takao Hayakawa, Takashi Aoi, Akihiro Umezawa, Keiya Ozawa, Yoji Sato, Yoshiki Sawa, Akifumi Matsuyama, Shinya Yamanaka, and Masayuki Yamato. Study on Ensuring the Quality and Safety of Pharmaceuticals and Medical Devices Derived from Processing of Allogenic Human Induced Pluripotent Stem Cell (-Like Cells). Regenerative Therapy 2015 in press.

5) Takao Hayakawa, Takashi Aoi, Akihiro Umezawa, Keiya Ozawa, Yoji Sato, Yoshiki Sawa, Akifumi Matsuyama, Shinya Yamanaka, and Masayuki Yamato. Study on Ensuring the Safety and Quality of Pharmaceuticals and Medical Devices Derived from the

- Processing of Human Embryonic Stem Cells. Regenerative Therapy 2015 in press.
- 6) Moriyama H, Moriyama M, Isshi H, Ishihara S, Okura H, Ichinose A, Ozawa T, Matsuyama A, Hayakawa T. Role of notch signaling in the maintenance of human mesenchymal stem cells under hypoxic conditions. *Stem Cells Dev.* 2014 Sep;23(18):2211-24.
 - 7) Moriyama M, Moriyama H, Uda J, Matsuyama A, Osawa M, Hayakawa T. BNIP3 plays crucial roles in the differentiation and maintenance of epidermal keratinocytes. *J Invest Dermatol.* 2014 Jun;134(6):1627-35.
 - 8) Takayama K, Kawabata K, Nagamoto Y, Inamura M, Ohashi K, Okuno H, Yamaguchi T, Tashiro K, Sakurai F, Hayakawa T, Okano T, Furue MK, Mizuguchi H. CCAAT/enhancer binding protein-mediated regulation of TGF β receptor 2 expression determines the hepatoblast fate decision. *Development.* 2014 Jan;141(1):91-100.
 - 9) Yagi Y, Kakehi K, Hayakawa T, Suzuki S. Application of microchip electrophoresis sodium dodecyl sulfate for the evaluation of change of degradation species of therapeutic antibodies in stability testing. *Anal Sci.* 2014;30(4):483-8.
 - 10) Toshio Morikawa, Kiyofumi Ninomiya, Katsuya Imura, Takahiro Yamaguchi, Yoshinori Akagi, Masayuki Yoshikawa, Takao Hayakawa, Osamu Muraoka, Hepatoprotective triterpenes from traditional Tibetan medicine *Potentilla anserina*. *Phytochemistry*, **102**, 169—181 (2014).
 - 11) Toshio Morikawa, Yusuke Nakanishi, Kiyofumi Ninomiya, Hisashi Matsuda, Souichi Nakashima, Hisako Miki, Yu Miyashita, Masayuki Yoshikawa, Takao Hayakawa, Osamu Muraoka, Dimeric pyrrolidinoindoline-type alkaloids with melanogenesis inhibitory activity in flower buds of *Chimonanthus praecox*. *J. Nat. Med.*, **68**, 539—549 (2014).
 - 12) Takao Hayakawa, Takashi Aoi, Akihiro Umezawa, Keiya Ozawa, Yoji Sato, Yoshiki Sawa, Akifumi Matsuyama, Shinya Yamanaka, and Masayuki Yamato. A Study on Ensuring the Quality and Safety of Pharmaceuticals and Medical Devices Derived from the Processing of Autologous Human Somatic Stem Cells. Regenerative Therapy 2015 in press.
 - 13) Takao Hayakawa, Takashi Aoi, Akihiro Umezawa, Keiya Ozawa, Yoji Sato, Yoshiki Sawa, Akifumi Matsuyama, Shinya Yamanaka, and Masayuki Yamato. A Study on Ensuring the Quality and Safety of Pharmaceuticals and Medical Devices Derived from the Processing of Allogenic Human Somatic Stem Cells. Regenerative Therapy 2015 in press.
 - 14) Takao Hayakawa, Takashi Aoi, Akihiro Umezawa, Keiya Ozawa, Yoji Sato, Yoshiki Sawa, Akifumi Matsuyama, Shinya Yamanaka, and Masayuki Yamato. A Study on Ensuring the Quality and Safety of Pharmaceuticals and Medical Devices Derived from Processing of Autologous Human Induced Pluripotent Stem Cell (-Like Cells). Regenerative Therapy 2015 in press.
 - 15) Takao Hayakawa, Takashi Aoi, Akihiro Umezawa, Keiya Ozawa,

- Yoji Sato, Yoshiki Sawa, Akifumi Matsuyama, Shinya Yamanaka, and Masayuki Yamato. A Study on Ensuring the Quality and Safety of Pharmaceuticals and Medical Devices Derived from Processing of Allogenic Human Induced Pluripotent Stem Cell (-Like Cells). *Regenerative Therapy* 2015 in press.
- 16) Takao Hayakawa, Takashi Aoi, Akihiro Umezawa, Keiya Ozawa, Yoji Sato, Yoshiki Sawa, Akifumi Matsuyama, Shinya Yamanaka, and Masayuki Yamato. A Study on Ensuring the Safety and Quality of Pharmaceuticals and Medical Devices Derived from the Processing of Human Embryonic Stem Cells. *Regenerative Therapy* 2015 in press.
- 17) Oshima N, Yamada Y, Nagayama S, Kawada K, Hasegawa S, Okabe H, Sakai Y, Aoi T. Induction of cancer stem cell properties in colon cancer cells by defined factors. *PLoS One*. 2014 Jul 9;9(7):e101735.
- 18) Oshima N, Yamada Y, Nagayama S, Kawada K, Hasegawa S, Okabe H, Sakai Y, Aoi T. Induction of cancer stem cell properties in colon cancer cells by defined factors. *PLoS One*. 2014 Jul 9;9(7):e101735.
- 19) Takao Hayakawa, Takashi Aoi, Akihiro Umezawa, Keiya Ozawa, Yoji Sato, Yoshiki Sawa, Akifumi Matsuyama, Shinya Yamanaka, and Masayuki Yamato. A Study on Ensuring the Quality and Safety of Pharmaceuticals and Medical Devices Derived from the Processing of Autologous Human Somatic Stem Cells. *Regenerative Therapy* 2015 in press.
- 20) Takao Hayakawa, Takashi Aoi, Akihiro Umezawa, Keiya Ozawa, Yoji Sato, Yoshiki Sawa, Akifumi Matsuyama, Shinya Yamanaka, and Masayuki Yamato. A Study on Ensuring the Quality and Safety of Pharmaceuticals and Medical Devices Derived from the Processing of Allogenic Human Induced Pluripotent Stem Cell (-Like Cells). *Regenerative Therapy* 2015 in press.
- 21) Takao Hayakawa, Takashi Aoi, Akihiro Umezawa, Keiya Ozawa, Yoji Sato, Yoshiki Sawa, Akifumi Matsuyama, Shinya Yamanaka, and Masayuki Yamato. A Study on Ensuring the Quality and Safety of Pharmaceuticals and Medical Devices Derived from Processing of Autologous Human Induced Pluripotent Stem Cell (-Like Cells). *Regenerative Therapy* 2015 in press.
- 22) Takao Hayakawa, Takashi Aoi, Akihiro Umezawa, Keiya Ozawa, Yoji Sato, Yoshiki Sawa, Akifumi Matsuyama, Shinya Yamanaka, and Masayuki Yamato. A Study on Ensuring the Quality and Safety of Pharmaceuticals and Medical Devices Derived from Processing of Allogenic Human Induced Pluripotent Stem Cell (-Like Cells). *Regenerative Therapy* 2015 in press.
- 23) Takao Hayakawa, Takashi Aoi, Akihiro Umezawa, Keiya Ozawa, Yoji Sato, Yoshiki Sawa, Akifumi Matsuyama, Shinya Yamanaka, and Masayuki Yamato. A Study on Ensuring the Safety and Quality of Pharmaceuticals and Medical Devices Derived from the Processing of Human Embryonic Stem Cells. *Regenerative Therapy* 2015 in press.
- 24) Inoue T, Umezawa A, Takenaka T, Suzuki H, Okada H. The contribution of epithelial-mesenchymal transition

- to renal fibrosis differs among kidney disease models. *Kidney Int.* 2015 Jan;87(1):233-8.
- 25) Lu S, Kanekura K, Hara T, Mahadevan J, Spears LD, Oslowski CM, Martinez R, Yamazaki-Inoue M, Toyoda M, Neilson A, Blanner P, Brown CM, Semenkovich CF, Marshall BA, Hershey T, Umezawa A, Greer PA, Urano F. A calcium-dependent protease as a potential therapeutic target for Wolfram syndrome. *Proc Natl Acad Sci U S A.* 2014 Dec 9;111(49):E5292-301.
- 26) Mizutani T, Kawabe S, Ishikane S, Imamichi Y, Umezawa A, Miyamoto K. Identification of novel steroidogenic factor 1 (SF-1)-target genes and components of the SF-1 nuclear complex. *Mol Cell Endocrinol.* 2014 Nov 25. pii: S0303-7207(14)00384-0. doi: 10.1016/j.mce.2014.11.019. [Epub ahead of print] Review. PubMed PMID: 25463758.
- 27) Ihara N, Umezawa A, Onami N, Tsumura H, Inoue E, Hayashi S, Sago H, Mizutani S. "Partial rescue of Mucopolysaccharidosis Type VII mice with a lifelong engraftment of allogeneic stem cells in utero". *Congenit Anom (Kyoto).* 2014 Nov 24.
- 28) Fukuda A, Tomikawa J, Miura T, Hata K, Nakabayashi K, Eggan K, Akutsu H, Umezawa A. The role of maternal-specific H3K9me3 modification in establishing imprinted X-chromosome inactivation and embryogenesis in mice. *Nat Commun.* 2014 Nov 14;5:5464.
- 29) Izumi Y, Suzuki E, Kanzaki S, Yatsuga S, Kinjo S, Igarashi M, Maruyama T, Sano S, Horikawa R, Sato N, Nakabayashi K, Hata K, Umezawa A, Ogata T, Yoshimura Y, Fukami M. Genome-wide copy number analysis and systematic mutation screening in 58 patients with hypogonadotropic hypogonadism. *Fertil Steril.* 2014 Oct;102(4):1130-1136.e3.
- 30) Nishi M, Akutsu H, Kudoh A, Kimura H, Yamamoto N, Umezawa A, Lee SW, Ryo A. Induced cancer stem-like cells as a model for biological screening and discovery of agents targeting phenotypic traits of cancer stem cell. *Oncotarget.* 2014 Sep 30;5(18):8665-80.
- 31) Igawa K, Kokubu C, Yusa K, Horie K, Yoshimura Y, Yamauchi K, Suemori H, Yokozeki H, Toyoda M, Kiyokawa N, Okita H, Miyagawa Y, Akutsu H, Umezawa A, Katayama I, Takeda J. Removal of reprogramming transgenes improves the tissue reconstitution potential of keratinocytes generated from human induced pluripotent stem cells. *Stem Cells Transl Med.* 2014 Sep;3(9):992-1001.
- 32) Kami D, Kitani T, Kishida T, Mazda O, Toyoda M, Tomitaka A, Ota S, Ishii R, Takemura Y, Watanabe M, Umezawa A, Gojo S. Pleiotropic functions of magnetic nanoparticles for ex vivo gene transfer. *Nanomedicine.* 2014 Aug;10(6):1165-74.
- 33) Ichida JK, TCW J, Williams LA, Carter AC, Shi Y, Moura MT, Ziller M, Singh S, Amabile G, Bock C, Umezawa A, Rubin LL, Bradner JE, Akutsu H, Meissner A, Eggan K. Notch inhibition allows oncogene-independent generation of iPS cells. *Nat Chem Biol.* 2014 Aug;10(8):632-9.
- 34) Fukawatase Y, Toyoda M,

- Okamura K, Nakamura K, Nakabayashi K, Takada S, Yamazaki-Inoue M, Masuda A, Nasu M, Hata K, Hanaoka K, Higuchi A, Takubo K, Umezawa A. Ataxia telangiectasia derived iPS cells show preserved x-ray sensitivity and decreased chromosomal instability. *Sci Rep*. 2014 Jun 27;4:5421.
- 35) Migita O, Maehara K, Kamura H, Miyakoshi K, Tanaka M, Morokuma S, Fukushima K, Shimamoto T, Saito S, Sago H, Nishihama K, Abe K, Nakabayashi K, Umezawa A, Okamura K, Hata K. Compilation of copy number variants identified in phenotypically normal and parous Japanese women. *J Hum Genet*. 2014 Jun;59(6):326-31.
- 36) Kawano N, Miyado K, Yoshii N, Kanai S, Saito H, Miyado M, Inagaki N, Odawara Y, Hamatani T, Umezawa A. Absence of CD9 reduces endometrial VEGF secretion and impairs uterine repair after parturition. *Sci Rep*. 2014 Apr 16;4:4701.
- 37) Sugawara K, Hamatani T, Yamada M, Ogawa S, Kamijo S, Kuji N, Akutsu H, Miyado K, Yoshimura Y, Umezawa A. Derivation of human decidua-like cells from amnion and menstrual blood. *Sci Rep*. 2014 Apr 8;4:4599. doi: 10.1038/srep04599.
- 38) Seko Y, Azuma N, Ishii T, Komuta Y, Miyamoto K, Miyagawa Y, Kaneda M, Umezawa A. Derivation of human differential photoreceptor cells from adult human dermal fibroblasts by defined combinations of CRX, RAX, OTX2 and NEUROD. *Genes Cells*. 2014 Mar;19(3):198-208.
- 39) Nishi M, Sakai Y, Akutsu H, Nagashima Y, Quinn G, Masui S, Kimura H, Perrem K, Umezawa A, Yamamoto N, Lee SW, Ryo A. Induction of cells with cancer stem cell properties from nontumorigenic human mammary epithelial cells by defined reprogramming factors. *Oncogene*. 2014 Jan 30;33(5):643-52.
- 40) Kaneko S, Bonasio R, Saldaña-Meyer R, Yoshida T, Son J, Nishino K, Umezawa A, Reinberg D. Interactions between JARID2 and noncoding RNAs regulate PRC2 recruitment to chromatin. *Mol Cell*. 2014 Jan 23;53(2):290-300.
- 41) Suzuki E, Yatsuga S, Igarashi M, Miyado M, Nakabayashi K, Hayashi K, Hata K, Umezawa A, Yamada G, Ogata T, Fukami M. De novo frameshift mutation in fibroblast growth factor 8 in a male patient with gonadotropin deficiency. *Horm Res Paediatr*. 2014;81(2):139-44.
- 42) Tano K, Yasuda S, Kuroda T, Saito H, Umezawa A, Sato Y. A novel in vitro method for detecting undifferentiated human pluripotent stem cells as impurities in cell therapy products using a highly efficient culture system. *PLoS One*. 2014 Oct 27;9(10):e110496.
- 43) Ninomiya E, Hattori T, Toyoda M, Umezawa A, Hamazaki T, Shintaku H. Glucocorticoids promote neural progenitor cell proliferation derived from human induced pluripotent stem cells. *Springerplus*. 2014 Sep 15;3:527.
- 44) Akihiro Umezawa, Keiya Ozawa, Yoji Sato, Yoshiki Sawa, Akifumi Matsuyama, Shinya Yamanaka, and Masayuki Yamato. A Study on Ensuring the Quality and Safety of Pharmaceuticals and Medical Devices Derived from the

- Processing of Autologous Human Somatic Stem Cells. *Regenerative Therapy* 2015 in press.
- 45) Takao Hayakawa, Takashi Aoi, Akihiro Umezawa, Keiya Ozawa, Yoji Sato, Yoshiki Sawa, Akifumi Matsuyama, Shinya Yamanaka, and Masayuki Yamato. A Study on Ensuring the Quality and Safety of Pharmaceuticals and Medical Devices Derived from the Processing of Allogenic Human Somatic Stem Cells. *Regenerative Therapy* 2015 in press.
- 46) Takao Hayakawa, Takashi Aoi, Akihiro Umezawa, Keiya Ozawa, Yoji Sato, Yoshiki Sawa, Akifumi Matsuyama, Shinya Yamanaka, and Masayuki Yamato. A Study on Ensuring the Quality and Safety of Pharmaceuticals and Medical Devices Derived from Processing of Autologous Human Induced Pluripotent Stem Cell (-Like Cells). *Regenerative Therapy* 2015 in press.
- 47) Takao Hayakawa, Takashi Aoi, Akihiro Umezawa, Keiya Ozawa, Yoji Sato, Yoshiki Sawa, Akifumi Matsuyama, Shinya Yamanaka, and Masayuki Yamato. A Study on Ensuring the Quality and Safety of Pharmaceuticals and Medical Devices Derived from Processing of Allogenic Human Induced Pluripotent Stem Cell (-Like Cells). *Regenerative Therapy* 2015 in press.
- 48) Takao Hayakawa, Takashi Aoi, Akihiro Umezawa, Keiya Ozawa, Yoji Sato, Yoshiki Sawa, Akifumi Matsuyama, Shinya Yamanaka, and Masayuki Yamato. A Study on Ensuring the Safety and Quality of Pharmaceuticals and Medical Devices Derived from the Processing of Human Embryonic Stem Cells. *Regenerative Therapy* 2015 in press.
- 49) Hatano K, Nagai T, Matsuyama T, Sakaguchi Y, Fujiwara S, Oh I, Muroi K, Ozawa K. Leukemia Cells Directly Phagocytose Blood Cells in AML-Associated Hemophagocytic Lymphohistiocytosis: A Case Report and Review of the Literature. *Acta Haematol.* 2015;133(1):98-100.
- 50) Cui W, Mizukami H, Yanagisawa M, Aida T, Nomura M, Isomura Y, Takayanagi R, Ozawa K, Tanaka K, Aizawa H. Glial dysfunction in the mouse habenula causes depressive-like behaviors and sleep disturbance. *J Neurosci.* 2014 Dec 3;34(49):16273-85.
- 51) Tsukahara T, Iwase N, Kawakami K, Iwasaki M, Yamamoto C, Ohmine K, Uchibori R, Teruya T, Ido H, Saga Y, Urabe M, Mizukami H, Kume A, Nakamura M, Brentjens R, Ozawa K. The Tol2 transposon system mediates the genetic engineering of T-cells with CD19-specific chimeric antigen receptors for B-cell malignancies. *Gene Ther.* 2014 Nov 27.
- 52) Suzuki T, Oh I, Ohmine K, Meguro A, Mori M, Fujiwara SI, Yamamoto C, Nagai T, Ozawa K. Distribution of serum erythropoietin levels in Japanese patients with myelodysplastic syndromes. *Int J Hematol.* 2014 Nov 6.
- 53) Mimuro J, Mizukami H, Shima M, Matsushita T, Taki M, Muto S, Higasa S, Sakai M, Ohmori T, Madoiwa S, Ozawa K, Sakata Y. The prevalence of neutralizing antibodies against adeno-associated virus capsids is reduced in young Japanese individuals. *J Med Virol.* 2014 Nov;86(11):1990-7.

- 54) Watakabe A, Ohtsuka M, Kinoshita M, Takaji M, Isa K, Mizukami H, Ozawa K, Isa T, Yamamori T. Comparative analyses of adeno-associated viral vector serotypes 1,2, 5, 8 and 9 in marmoset, mouse and macaque cerebral cortex. *Neurosci Res.* 2014 Sep 18. pii: S0168-0102(14)00213-2.
- 55) Okabe H, Suzuki T, Uehara E, Ueda M, Nagai T, Ozawa K. The bone marrow hematopoietic microenvironment is impaired in iron-overloaded mice. *Eur J Haematol.* 2014 Aug;93(2):118-28.
- 56) Sripayap P, Nagai T, Uesawa M, Kobayashi H, Tsukahara T, Ohmine K, Muroi K, Ozawa K. Mechanisms of resistance to azacitidine in human leukemia cell lines. *Exp Hematol.* 2014 Apr;42(4):294-306.e2.
- 57) Ozawa K. Guest editorial: recent progress in gene therapy. *Int J Hematol.* 2014 Apr;99(4):359-60.
- 58) Uchibori R, Tsukahara T, Ohmine K, Ozawa K. Cancer gene therapy using mesenchymal stem cells. *Int J Hematol.* 2014 Apr;99(4):377-82.
- 59) Sripayap P, Nagai T, Hatano K, Kikuchi J, Furukawa Y, Ozawa K. Romidepsin overcomes cell adhesion-mediated drug resistance in multiple myeloma cells. *Acta Haematol.* 2014;132(1):1-4.
- 60) Uehara T, Kanazawa T, Mizukami H, Uchibori R, Tsukahara T, Urabe M, Kume A, Misawa K, Carey TE, Suzuki M, Ichimura K, Ozawa K. Novel anti-tumor mechanism of galanin receptor type 2 in head and neck squamous cell carcinoma cells. *Cancer Sci.* 2014 Jan;105(1):72-80.
- 61) Fujiwara S, Muroi K, Tatara R, Ohmine K, Matsuyama T, Mori M, Nagai T, Ozawa K. Intrathecal administration of high-titer cytomegalovirus immunoglobulin for cytomegalovirus meningitis. *Case Rep Hematol.* 2014;2014:272458.
- 62) Watakabe A, Takaji M, Kato S, Kobayashi K, Mizukami H, Ozawa K, Ohsawa S, Matsui R, Watanabe D, Yamamori T. Simultaneous visualization of extrinsic and intrinsic axon collaterals in Golgi-like detail for mouse corticothalamic and corticocortical cells: a double viral infection method. *Front Neural Circuits.* 2014 Sep 17;8:110.
- 63) Kashiwakura Y, Ohmori T, Mimuro J, Madoiwa S, Inoue M, Hasegawa M, Ozawa K, Sakata Y. Production of functional coagulation factor VIII from iPSCs using a lentiviral vector. *Haemophilia.* 2014 Jan;20(1):e40-4.
- 64) Tatara R, Sato M, Fujiwara S, Oh I, Muroi K, Ozawa K, Nagai T. Hemoperfusion for Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis. *Intern Med.* 2014;53(20):2365-8.
- 65) Muroi K, Fujiwara S, Tatara R, Sato K, Oh I, Ohmine K, Suzuki T, Nagai T, Ozawa K, Kanda Y. Two granulocytic regions in bone marrow with eosinophilia evaluated by flow cytometry. *J Clin Exp Hematop.* 2014;54(3):243-5.
- 66) Akihiro Umezawa, Keiia Ozawa, Yoji Sato, Yoshiki Sawa, Akifumi Matsuyama, Shinya Yamanaka, and Masayuki Yamato. Study on Ensuring the Quality and Safety of Pharmaceuticals and Medical Devices Derived from the Processing of Autologous Human Somatic Stem Cells. *Regenerative Therapy* 2015 in press.
- 67) Takao Hayakawa, Takashi Aoi, Akihiro Umezawa, Keiia Ozawa,

- Yoji Sato, Yoshiki Sawa, Akifumi Matsuyama, Shinya Yamanaka, and Masayuki Yamato. Study on Ensuring the Quality and Safety of Pharmaceuticals and Medical Devices Derived from the Processing of Allogenic Human Somatic Stem Cells. Regenerative Therapy 2015 in press.
- 68) Takao Hayakawa, Takashi Aoi, Akihiro Umezawa, Keiya Ozawa, Yoji Sato, Yoshiki Sawa, Akifumi Matsuyama, Shinya Yamanaka, and Masayuki Yamato. Study on Ensuring the Quality and Safety of Pharmaceuticals and Medical Devices Derived from Processing of Autologous Human Induced Pluripotent Stem Cell (-Like Cells). Regenerative Therapy 2015 in press.
- 69) Takao Hayakawa, Takashi Aoi, Akihiro Umezawa, Keiya Ozawa, Yoji Sato, Yoshiki Sawa, Akifumi Matsuyama, Shinya Yamanaka, and Masayuki Yamato. Study on Ensuring the Quality and Safety of Pharmaceuticals and Medical Devices Derived from Processing of Allogenic Human Induced Pluripotent Stem Cell (-Like Cells). Regenerative Therapy 2015 in press.
- 70) Takao Hayakawa, Takashi Aoi, Akihiro Umezawa, Keiya Ozawa, Yoji Sato, Yoshiki Sawa, Akifumi Matsuyama, Shinya Yamanaka, and Masayuki Yamato. Study on Ensuring the Safety and Quality of Pharmaceuticals and Medical Devices Derived from the Processing of Human Embryonic Stem Cells. Regenerative Therapy 2015 in press.
- 71) Kusakawa S, Machida K, Yasuda S, Takada N, Kuroda T, Sawada R, Okura H, Tsutsumi H, Kawamata S, Sato Y. Characterization of in vivo tumorigenicity tests using severe immunodeficient NOD/Shi-scid IL2Rynull mice for detection of tumorigenic cellular impurities in human cell-processed therapeutic products. Regen Ther., in press.
- 72) Kono K, Takada N, Yasuda S, Sawada R, Niimi S, Matsuyama A, Sato Y. Characterization of the cell growth analysis for detection of immortal cellular impurities in human mesenchymal stem cells. Biologicals., in press.
- 73) Tano K, Yasuda S, Kuroda T, Saito H, Umezawa A, Sato Y. A novel in vitro method for detecting undifferentiated human pluripotent stem cells as impurities in cell therapy products using a highly efficient culture system. PLoS One. 2014;9:e110496.
- 74) 佐藤陽治 再生医療と薬学 ファルマシア 2014;50:1213-5.
- 75) 佐藤陽治 ヒト多能性幹細胞加工製品に残存する未分化多能性幹細胞の高感度検出法の開発 再生医療 2014;13:432-5.
- 76) 村岡ひとみ, 佐藤陽治 再生医療・細胞治療の規制動向とレギュラトリーサイエンス DDS. 2014;29:207-16.
- 77) 中島啓行, 佐藤陽治 薬事法改正と再生医療等安全性確保法を踏まえた再生医療／細胞治療の開発 ファームステージ 2014;10:1-5.
- 78) 三浦巧, 佐藤陽治 再生医療・細胞治療に使用する細胞加工物の品質・安全性評価の原則と造腫瘍性の考え方 谷本学校毒性質問箱 2014;16:1-10.
- 79) 佐藤陽治 再生医療／細胞治療における細胞培養に関する規制 『再生医療の細胞培養技術開発と応用展開』(監修: 紀ノ岡正博) 株式会社シーエムシー出版, 東京 (2014), pp. 27-36.
- 80) 草川森士, 佐藤陽治 再生医療製品の造腫瘍性評価 最新医学

- 2014;69(3)増刊号:745-765.
- 81) 佐藤大作, 佐藤陽治 規制関連 『再生医療用語集』(印刷中)
 - 82) 村岡ひとみ, 佐藤陽治 再生医療・細胞治療の臨床研究から実用化までの道のり Geriatric Medicine (老年医学) 2014;52(3):237-239.
 - 83) 佐藤陽治 ヒト iPS 細胞由来移植細胞中に混入する造腫瘍性細胞／未分化細胞の in vitro 検出法 Cytometry Research 2014;24(1): 7-11.
 - 84) 安田智, 佐藤陽治 再生医療製品の品質関連規制と対応の留意点 『動物細胞培養の手法と細胞死・増殖不良・細胞変異を防止する技術』(編集: 技術情報協会) 技術情報協会, 東京 (2014), pp. 517-22.
 - 85) Takao Hayakawa, Takashi Aoi, Akihiro Umezawa, Keiya Ozawa, Yoji Sato, Yoshiki Sawa, Akifumi Matsuyama, Shinya Yamanaka, and Masayuki Yamato. A Study on Ensuring the Quality and Safety of Pharmaceuticals and Medical Devices Derived from the Processing of Autologous Human Somatic Stem Cells. Regenerative Therapy 2015 in press.
 - 86) Takao Hayakawa, Takashi Aoi, Akihiro Umezawa, Keiya Ozawa, Yoji Sato, Yoshiki Sawa, Akifumi Matsuyama, Shinya Yamanaka, and Masayuki Yamato. A Study on Ensuring the Quality and Safety of Pharmaceuticals and Medical Devices Derived from the Processing of Allogenic Human Somatic Stem Cells. Regenerative Therapy 2015 in press.
 - 87) Takao Hayakawa, Takashi Aoi, Akihiro Umezawa, Keiya Ozawa, Yoji Sato, Yoshiki Sawa, Akifumi Matsuyama, Shinya Yamanaka, and Masayuki Yamato. A Study on Ensuring the Quality and Safety of Pharmaceuticals and Medical Devices Derived from Processing of Autologous Human Induced Pluripotent Stem Cell (-Like Cells). Regenerative Therapy 2015 in press.
 - 88) Takao Hayakawa, Takashi Aoi, Akihiro Umezawa, Keiya Ozawa, Yoji Sato, Yoshiki Sawa, Akifumi Matsuyama, Shinya Yamanaka, and Masayuki Yamato. A Study on Ensuring the Quality and Safety of Pharmaceuticals and Medical Devices Derived from Processing of Allogenic Human Induced Pluripotent Stem Cell (-Like Cells). Regenerative Therapy 2015 in press.
 - 89) Takao Hayakawa, Takashi Aoi, Akihiro Umezawa, Keiya Ozawa, Yoji Sato, Yoshiki Sawa, Akifumi Matsuyama, Shinya Yamanaka, and Masayuki Yamato. A Study on Ensuring the Safety and Quality of Pharmaceuticals and Medical Devices Derived from the Processing of Human Embryonic Stem Cells. Regenerative Therapy 2015 in press.
 - 90) Toda K, Sawa Y. Clinical management for complications related to implantable LVAD use. Gen Thorac Cardiovasc Surg. 2015 Jan;63(1):1-7.
 - 91) Yunoki J, Kuratani T, Shirakawa Y, Torikai K, Shimamura K, Kin K, Sawa Y. Mid-term results of endovascular treatment with the Gore TAG device for degenerative descending thoracic aortic aneurysms. Gen Thorac Cardiovasc Surg. 2015 Jan;63(1):38-42.
 - 92) Sawa Y, Takayama M, Mitsudo K, Nanto S, Takanashi S, Komiya T, Kuratani T, Tobaru T, Goto T. Clinical efficacy of transcatheter aortic valve replacement for severe aortic stenosis in high-risk patients: the PREVAIL JAPAN

- trial. *Surg Today*. 2015 Jan;45(1):34-43.
- 93) Nishi H, Toda K, Miyagawa S, Yoshikawa Y, Fukushima S, Kawamura M, Saito T, Yoshioka D, Daimon T, Sawa Y. Novel Method of Evaluating Liver Stiffness Using Transient Elastography to Evaluate Perioperative Status in Severe Heart Failure. *Circ J*. 2014 Dec 10.
- 94) Yoshioka D, Toda K, Yoshikawa Y, Sawa Y. Over 1200-day support with dual Jarvik 2000 biventricular assist device. *Interact Cardiovasc Thorac Surg*. 2014 Dec;19(6):1083-4.
- 95) Kashiyama N, Toda K, Miyagawa S, Nishi H, Yoshikawa Y, Fukushima S, Yoshioka D, Saito T, Sawa Y. Initial experience of EVAHEART explantation after continuous-flow LVAD off test with percutaneous occlusion balloon. *J Artif Organs*. 2014 Dec;17(4):366-9.
- 96) Yoshioka D, Matsumiya G, Toda K, Sakaguchi T, Yoshikawa Y, Saito S, Matsuda H, Sawa Y. Clinical results with Jarvik 2000 axial flow left ventricular assist device: Osaka University Experience. *J Artif Organs*. 2014 Dec;17(4):308-14.
- 97) Yunoki J, Kuratani T, Shirakawa Y, Torikai K, Shimamura K, Kin K, Sawa Y. Clinical experience with the RELAY NBS PLUS stent-graft for aortic arch pathology. *Surg Today*. 2014 Dec;44(12):2263-8.
- 98) Kainuma S, Miyagawa S, Fukushima S, Pearson J, Chen YC, Saito A, Harada A, Shiozaki M, Iseoka H, Watabe T, Watabe H, Horitsugi G, Ishibashi M, Ikeda H, Tsuchimochi H, Sonobe T, Fujii Y, Naito H, Umetani K, Shimizu T, Okano T, Kobayashi E, Daimon T, Ueno T, Kuratani T, Toda K, Takakura N, Hatazawa J, Shirai M, Sawa Y. Cell-sheet Therapy with Omentopexy Promotes Arteriogenesis and Improves Coronary Circulation Physiology in Failing Heart. *Mol Ther*. 2014 Nov 25.
- 99) Kamata S, Miyagawa S, Fukushima S, Imanishi Y, Saito A, Maeda N, Shimomura I, Sawa Y. Targeted Delivery of Adipocytokines Into the Heart by Induced Adipocyte Cell-Sheet Transplantation Yields Immune Tolerance and Functional Recovery in Autoimmune-Associated Myocarditis in Rats. *Circ J*. 2014 Nov 5.
- 100) Saito S, Toda K, Miyagawa S, Yoshikawa Y, Fukushima S, Sakata Y, Mizote I, Daimon T, Sawa Y. Hemodynamic changes during left ventricular assist device-off test correlate with the degree of cardiac fibrosis and predict the outcome after device explantation. *J Artif Organs*. 2014 Nov 5. [Epub ahead of print] PubMed
- 101) Watanabe Y, Miyagawa S, Fukushima S, Daimon T, Shirakawa Y, Kuratani T, Sawa Y. Development of a prostacyclin-agonist-eluting aortic stent graft enhancing biological attachment to the aortic wall. *J Thorac Cardiovasc Surg*. 2014 Nov;148(5):2325-2334.e1.
- 102) Uchinaka A, Kawaguchi N, Mori S, Hamada Y, Miyagawa S, Saito A, Sawa Y, Matsuura N. Tissue inhibitor of metalloproteinase-1 and -3 improves cardiac function in an ischemic cardiomyopathy model rat. *Tissue Eng Part A*. 2014 Nov;20(21-22):3073-84.

- 103) Kashiya N, Kuratani T, Torikai K, Maeda K, Toda K, Miyagawa S, Nishi H, Yoshikawa Y, Fukushima S, Yoshioka D, Saito T, Sawa Y. Urgent transcatheter aortic valve replacement for severe aortic valve stenosis with acute decompensated heart failure: report of a case. *Surg Today*. 2014 Oct 31.
- 104) Kashiya N, Toda K, Miyagawa S, Nishi H, Yoshikawa Y, Fukushima S, Yoshioka D, Masashi K, Saito T, Sawa Y. Off-pump coronary artery bypass grafting via median sternotomy in a patient with a history of esophagectomy with substernal gastric tube reconstruction: report of a case. *Surg Today*. 2014 Oct 29.
- 105) Maeda K, Nishi H, Sakaguchi T, Miyagawa S, Ueno T, Kuratani T, Sawa Y. Coronary artery bypass grafting in a patient initially presenting with systemic lupus erythematosus. *Ann Thorac Cardiovasc Surg*. 2014 Oct 20;20(5):414-7.
- 106) Maeda K, Kuratani T, Torikai K, Mizote I, Iritakenishi T, Takeda Y, Nakatani S, Nanto S, Toda K, Sawa Y. Transcatheter aortic valve replacement for patients with aortic valve stenosis complicated with moyamoya disease. *Ann Thorac Surg*. 2014 Oct;98(4):1443-5.
- 107) Takeuchi M, Kuratani T, Miyagawa S, Shirakawa Y, Shimamura K, Kin K, Yoshida T, Arai Y, Hoashi T, Teramoto N, Hirakawa K, Kawaguchi N, Sawa Y. Tissue-engineered stent-graft integrates with aortic wall by recruiting host tissue into graft scaffold. *J Thorac Cardiovasc Surg*. 2014 Oct;148(4) 1719-25.
- 108) Ozawa H, Ueno T, Iwai S, Kawata H, Nishigaki K, Kishimoto H, Sawa Y. Contractility-afterload mismatch in patients with protein-losing enteropathy after the Fontan operation. *Pediatr Cardiol*. 2014 Oct;35(7):1225-31.
- 109) Ishimaru K, Miyagawa S, Fukushima S, Ide H, Hoashi T, Shibuya T, Ueno T, Sawa Y. Functional and pathological characteristics of reversible remodeling in a canine right ventricle in response to volume overloading and volume unloading. *Surg Today*. 2014 Oct;44(10):1935-45.
- 110) Masuda S, Miyagawa S, Fukushima S, Kawamura T, Kashiya N, Saito A, Sawa Y. Regulating ES or induced pluripotent stem cells by innate lymphoid cells. *Transplantation*. 2014 Sep 15;98(5):e38-9.
- 111) 27) Iguchi N, Uchiyama A, Ueta K, Sawa Y, Fujino Y. Neutrophil gelatinase-associated lipocalin and liver-type fatty acid-binding protein as biomarkers for acute kidney injury after organ transplantation. *J Anesth*. 2014 Sep 10. [
- 112) Yasui H, Lee JK, Yoshida A, Yokoyama T, Nakanishi H, Miwa K, Naito AT, Oka T, Akazawa H, Nakai J, Miyagawa S, Sawa Y, Sakata Y, Komuro I. Excitation propagation in three-dimensional engineered hearts using decellularized extracellular matrix. *Biomaterials*. 2014 Sep;35(27):7839-50.
- 113) Masuda S, Miyagawa S, Fukushima S, Sougawa N, Ito E, Takeda M, Saito A, Sawa Y. Emerging innovation towards safety in the clinical application of ESCs and iPSCs. *Nat Rev Cardiol*.

- 2014 Sep;11(9):553-4.
- 114) Hatta K, Otachi T, Fujita K, Morikawa F, Ito S, Tomiyama H, Abe T, Sudo Y, Takebayashi H, Yamashita T, Katayama S, Nakase R, Shirai Y, Usui C, Nakamura H, Ito H, Hirata T, Sawa Y; JAST study group. Antipsychotic switching versus augmentation among early non-responders to risperidone or olanzapine in acute-phase schizophrenia. *Schizophr Res*. 2014 Sep;158(1-3):213-22.
- 115) Sawa Y. Current status of third-generation implantable left ventricular assist devices in Japan, Duraheart and HeartWare. *Surg Today*. 2014 Aug 21. [Epub ahead of print].
- 116) Masuda H, Nakamura T, Mouri N, Sawa Y. Aortic valve replacement for quadricuspid valve: a lesson learnt from a negative experience. *Interact Cardiovasc Thorac Surg*. 2014 Aug;19(2):334-5.
- 117) Watanabe Y, Shimamura K, Yoshida T, Daimon T, Shirakawa Y, Torikai K, Sakamoto T, Shijo T, Toda K, Kuratani T, Sawa Y. Aortic remodeling as a prognostic factor for late aortic events after thoracic endovascular aortic repair in type B aortic dissection with patent false lumen. *J Endovasc Ther*. 2014 Aug;21(4):517-25.
- 118) Nishi H, Sakaguchi T, Miyagawa S, Yoshikawa Y, Fukushima S, Yoshioka D, Ueno T, Kuratani T, Sawa Y. Factors affecting a dilated ascending aorta in patients with bicuspid aortic valve: the relevance of valve anatomy, body size and age. *Surg Today*. 2014 Aug;44(8):1483-9.
- 119) Sawa Y. [Transcatheter aortic valve replacement]. *Kyobu Geka*. 2014 Jul;67(8):677-85. Japanese.
- 120) Watanabe Y, Hayashida K, Takayama M, Mitsudo K, Nanto S, Takanashi S, Komiya T, Kuratani T, Tobaru T, Goto T, Lefèvre T, Sawa Y, Morice MC. First direct comparison of clinical outcomes between European and Asian cohorts in transcatheter aortic valve implantation: The Massy study group vs. the PREVAIL JAPAN trial. *J Cardiol*. 2014 Jun 10. pii: S0914-5087(14)00146-4.
- 121) Yoshioka D, Toda K, Sakaguchi T, Okazaki S, Yamauchi T, Miyagawa S, Nishi H, Yoshikawa Y, Fukushima S, Saito T, Sawa Y; OSCAR study group. Valve surgery in active endocarditis patients complicated by intracranial haemorrhage: the influence of the timing of surgery on neurological outcomes. *Eur J Cardiothorac Surg*. 2014 Jun;45(6):1082-8.
- 122) Nishi H, Sakaguchi T, Miyagawa S, Yoshikawa Y, Fukushima S, Yoshioka D, Saito T, Toda K, Sawa Y. Optimal coronary artery bypass grafting strategy for acute coronary syndrome. *Gen Thorac Cardiovasc Surg*. 2014 Jun;62(6):357-63.
- 123) Kashiwama N, Masai T, Yoshitatsu M, Yamauchi T, Ogasawara Y, Matsunaga Y, Sawa Y. A simple way to treat mitral valve prolapse: chordal replacement using a new mitral leaflet retractor. *Interact Cardiovasc Thorac Surg*. 2014 Jun;18(6):701-5.
- 124) Nishi H, Toda K, Miyagawa S, Yoshikawa Y, Fukushima S, Saito S, Yoshioka D, Saito T, Ueno T, Sakaguchi T, Sawa Y. Initial experience in Japan with HeartWare ventricular assist

- system. *J Artif Organs*. 2014 Jun;17(2):149-56.
- 125) Saito S, Yamazaki K, Nishinaka T, Ichihara Y, Ono M, Kyo S, Nishimura T, Nakatani T, Toda K, Sawa Y, Tominaga R, Tanoue T, Saiki Y, Matsui Y, Takemura T, Niinami H, Matsumiya G; J-MACS Research Group. Post-approval study of a highly pulsed, low-shear-rate, continuous-flow, left ventricular assist device, EVAHEART: a Japanese multicenter study using J-MACS. *J Heart Lung Transplant*. 2014 Jun;33(6):599-608.
- 126) Wakasa S, Matsui Y, Isomura T, Takanashi S, Yamaguchi A, Komiya T, Cho Y, Kobayashi J, Yaku H, Kokaji K, Arai H, Sawa Y. Risk scores for predicting mortality after surgical ventricular reconstruction for ischemic cardiomyopathy: results of a Japanese multicenter study. *J Thorac Cardiovasc Surg*. 2014 Jun;147(6):1868-74, 1874.e1-2.
- 127) Sawa Y. Transcatheter aortic valve implantation. *Surg Today*. 2014 May 20.[Epub ahead of print].
- 128) Imai A, Gotoh K, Asano Y, Yamada N, Motooka D, Fukushima M, Kanzaki M, Ohtani T, Sakata Y, Nishi H, Toda K, Sawa Y, Komuro I, Horii T, Iida T, Nakamura S, Takashima S. Comprehensive metagenomic approach for detecting causative microorganisms in culture-negative infective endocarditis. *Int J Cardiol*. 2014 Mar 15;172(2):e288-9.
- 129) Sawa Y, Tatsumi E, Tsukiya T, Matsuda K, Fukunaga K, Kishida A, Masuzawa T, Matsumiya G, Myoui A, Nishimura M, Nishimura T, Nishinaka T, Okamoto E, Tokunaga S, Tomo T, Yagi Y, Yamaoka T; Journal of Artificial Organs Editorial Committee. Journal of Artificial Organs 2013: the year in review : Journal of Artificial Organs Editorial Committee. *J Artif Organs*. 2014 Mar;17(1):1-8.
- 130) Kubota Y, Miyagawa S, Fukushima S, Saito A, Watabe H, Daimon T, Sakai Y, Akita T, Sawa Y. Impact of cardiac support device combined with slow-release prostacyclin agonist in a canine ischemic cardiomyopathy model. *J Thorac Cardiovasc Surg*. 2014 Mar;147(3):1081-7.
- 131) Maeda K, Saito S, Toda T, Ueno T, Kuratani T, Sawa Y. Transient Constrictive Pericarditis Following Cardiac Surgery. *Ann Thorac Cardiovasc Surg*. 2014 Feb 4.[Epub ahead of print].
- 132) Taniguchi T, Sakata Y, Ohtani T, Mizote I, Takeda Y, Asano Y, Masuda M, Minamiguchi H, Kanzaki M, Ichibori Y, Nishi H, Toda K, Sawa Y, Komuro I. Usefulness of transient elastography for noninvasive and reliable estimation of right-sided filling pressure in heart failure. *Am J Cardiol*. 2014 Feb 1;113(3):552-8.
- 133) Shirakawa Y, Kuratani T, Shimamura K, Torikai K, Sakamoto T, Shijo T, Sawa Y. The efficacy and short-term results of hybrid thoracic endovascular repair into the ascending aorta for aortic arch pathologies. *Eur J Cardiothorac Surg*. 2014 Feb;45(2):298-304; discussion 304.
- 134) Kainuma S, Taniguchi K, Toda K, Funatsu T, Miyagawa S, Kondoh H, Masai T, Otake S, Yoshikawa Y, Nishi H, Sakaguchi T, Ueno T, Kuratani T, Daimon T, Sawa Y.

- Restrictive mitral annuloplasty with or without surgical ventricular reconstruction in ischaemic cardiomyopathy: impacts on neurohormonal activation, reverse left ventricular remodelling and survival. *Eur J Heart Fail.* 2014Feb;16(2):189-200.
- 135) Shudo Y, Miyagawa S, Ohkura H, Fukushima S, Saito A, Shiozaki M, Kawaguchi N, Matsuura N, Shimizu T, Okano T, Matsuyama A, Sawa Y. Addition of mesenchymal stem cells enhances the therapeutic effects of skeletal myoblast cell-sheet transplantation in a rat ischemic cardiomyopathy model. *Tissue Eng Part A.* 2014 Feb;20(3-4):728-39.
- 136) Hirano K, Tanaka T, Ikeda Y, Yamaguchi S, Zaima N, Kobayashi K, Suzuki A, Sakata Y, Sakata Y, Kobayashi K, Toda T, Fukushima N, Ishibashi-Ueda H, Tavian D, Nagasaka H, Hui SP, Chiba H, Sawa Y, Hori M. Genetic mutations in adipose triglyceride lipase and myocardial up-regulation of peroxisome proliferated activated receptor- γ in patients with triglyceride deposit cardiomyovascuopathy. *Biochem Biophys Res Commun.* 2014 Jan 10;443(2):574-9.
- 137) Ueshima S, Nishida T, Koike M, Matsuda H, Sawa Y, Uchiyama Y. Nitric oxide-mediated injury of interstitial cells of Cajal and intestinal dysmotility under endotoxemia of mice. *Biomed Res.* 2014;35(4):251-62.
- 138) Kamata S, Miyagawa S, Fukushima S, Nakatani S, Kawamoto A, Saito A, Harada A, Shimizu T, Daimon T, Okano T, Asahara T, Sawa Y. Improvement of cardiac stem cell sheet therapy for chronic ischemic injury by adding endothelial progenitor cell transplantation: analysis of layer-specific regional cardiac function. *Cell Transplant.* 2014;23(10):1305-19.
- 139) Sawa Y, Saito S, Kobayashi J, Niinami H, Kuratani T, Maeda K, Kanzaki H, Komiyama N, Tanaka Y, Boyle A, Zhang A, Moore BJ, de Medeiros R; MDT-2111 Japan Investigators. First clinical trial of a self-expandable transcatheter heart valve in Japan in patients with symptomatic severe aortic stenosis. *Circ J.* 2014;78(5):1083-90.
- 140) Matsuda T, Miyagawa S, Fukushima S, Kitagawa-Sakakida S, Akimaru H, Horii-Komatsu M, Kawamoto A, Saito A, Asahara T, Sawa Y. Human cardiac stem cells with reduced notch signaling show enhanced therapeutic potential in a rat acute infarction model. *Circ J.* 2014;78(1):222-31.
- 141) 57) Watanabe Y, Kuratani T, Shirakawa Y, Torikai K, Shimamura K, Sawa Y. Hybrid endovascular repair of a dissecting thoracoabdominal aortic aneurysm with stent graft implantation through the false lumen. *J Vasc Surg.* 2014 Jan;59(1):264-7.
- 142) Kawamura T, Miyagawa S, Fukushima S, Yoshida A, Kashiyama N, Kawamura A, Ito E, Saito A, Maeda A, Eguchi H, Toda K, Lee JK, Miyagawa S, Sawa Y. N-glycans: phenotypic homology and structural differences between myocardial cells and induced pluripotent stem cell-derived cardiomyocytes. *PLoS One.* 2014 Oct 30;9(10):e111064.
- 143) Hayakawa T, Aoi T, Umezawa A, Ozawa K, Yoji Sato, Sawa Y,

- Matsuyama A, Yamanaka S, Yamato M. Study on ensuring the quality and safety of pharmaceuticals and medical devices derived from processing of autologous human somatic stem cells, *Regenerative Therapy* 1, in press
- 144) Hayakawa T, Aoi T, Umezawa A, Ozawa K, Yoji Sato, Sawa Y, Matsuyama A, Yamanaka S, Yamato M. Study on ensuring the quality and safety of pharmaceuticals and medical devices derived from processing of allogenic human somatic stem cells. *Regenerative Therapy* 1, in press
- 145) Hayakawa T, Aoi T, Umezawa A, Ozawa K, Yoji Sato, Sawa Y, Matsuyama A, Yamanaka S, Yamato M. Study on ensuring the quality and safety of pharmaceuticals and medical devices derived from processing of autologous human induced pluripotent stem (-like) cells. *Regenerative Therapy* 1, in press
- 146) Hayakawa T, Aoi T, Umezawa A, Ozawa K, Yoji Sato, Sawa Y, Matsuyama A, Yamanaka S, Yamato M. Study on ensuring the quality and safety of pharmaceuticals and medical devices derived from processing of allogenic human induced pluripotent stem (-like) cells. *Regenerative Therapy* 1, in press
- 147) Hayakawa T, Aoi T, Umezawa A, Ozawa K, Yoji Sato, Sawa Y, Matsuyama A, Yamanaka S, Yamato M. Study on ensuring the quality and safety of pharmaceuticals and medical devices derived from processing of human embryonic stem (-like) cells. *Regenerative Therapy* 1, in press
- 148) Kono K, Takada N, Yasuda S, Sawada R, Niimi S, Matsuyama A, Sato Y. Characterization of the cell growth analysis for detection of immortal cellular impurities in human mesenchymal stem cells. *Biologicals*. 2014 Dec 16.
- 149) Okura H, Soeda M, Morita M, Fujita M, Naba K, Ito C, Ichinose A, Matsuyama A. Therapeutic potential of human adipose tissue-derived multi-lineage progenitor cells in liver fibrosis. *Biochem Biophys Res Commun*. 2014 Dec 6
- 150) Moriyama H, Moriyama M, Isshi H, Ishihara S, Okura H, Ichinose A, Ozawa T, Matsuyama A, Hayakawa T. Role of notch signaling in the maintenance of human mesenchymal stem cells under hypoxic conditions. *Stem Cells Dev*. 2014 Sep 15;23(18):2211-24.
- 151) Ozasa M, Sawada K, Iwayama T, Yamamoto S, Morimoto C, Okura H, Matsuyama A, Komoda H, Lee CM, Sawa Y, Kitamura M, Hashikawa T, Takedachi M and Murakami S. Periodontal tissue regeneration by transplantation of adipose tissue-derived multi-lineage progenitor cells. *Inflammation and Regeneration*, 2014, in press
- 152) 大倉華雪・松山晃文 細胞医療での申請にあたっての注意点—品質の観点から— 先進医療 NAVIGATOR II 再生医療・がん領域の実用化への TOPICS 2014. pp5-8
- 153) Takao Hayakawa, Takashi Aoi, Akihiro Umezawa, Keiya Ozawa, Yoji Sato, Yoshiki Sawa, Akifumi Matsuyama, Shinya Yamanaka, and Masayuki Yamato. A Study on Ensuring the Quality and Safety of Pharmaceuticals and Medical Devices Derived from the

- Processing of Autologous Human Somatic Stem Cells. Regenerative Therapy 2015 in press.
- 154) Takao Hayakawa, Takashi Aoi, Akihiro Umezawa, Keiya Ozawa, Yoji Sato, Yoshiki Sawa, Akifumi Matsuyama, Shinya Yamanaka, and Masayuki Yamato. A Study on Ensuring the Quality and Safety of Pharmaceuticals and Medical Devices Derived from the Processing of Allogenic Human Somatic Stem Cells. Regenerative Therapy 2015 in press.
- 155) Takao Hayakawa, Takashi Aoi, Akihiro Umezawa, Keiya Ozawa, Yoji Sato, Yoshiki Sawa, Akifumi Matsuyama, Shinya Yamanaka, and Masayuki Yamato. A Study on Ensuring the Quality and Safety of Pharmaceuticals and Medical Devices Derived from Processing of Autologous Human Induced Pluripotent Stem Cell (-Like Cells). Regenerative Therapy 2015 in press.
- 156) Takao Hayakawa, Takashi Aoi, Akihiro Umezawa, Keiya Ozawa, Yoji Sato, Yoshiki Sawa, Akifumi Matsuyama, Shinya Yamanaka, and Masayuki Yamato. A Study on Ensuring the Quality and Safety of Pharmaceuticals and Medical Devices Derived from Processing of Allogenic Human Induced Pluripotent Stem Cell (-Like Cells). Regenerative Therapy 2015 in press.
- 157) Takao Hayakawa, Takashi Aoi, Akihiro Umezawa, Keiya Ozawa, Yoji Sato, Yoshiki Sawa, Akifumi Matsuyama, Shinya Yamanaka, and Masayuki Yamato. A Study on Ensuring the Safety and Quality of Pharmaceuticals and Medical Devices Derived from the Processing of Human Embryonic Stem Cells. Regenerative Therapy 2015 in press.
- 158) Yamamoto K, Hama T, Yamato M, Uchimizu H, Sugiyama H, Takagi R, Yaguchi Y, Okano T, Kojima H. The effect of transplantation of nasal mucosal epithelial cellsheets after middle ear surgery in a rabbit model. *Biomaterials*. 2015Feb;42:87-93.
- 159) Tanaka N, Ota H, Fukumori K, Miyake J, Yamato M, Okano T. 'Erratum to "Micro-patterned cell-sheets fabricated with stamping-force-controlled micro-contact printing" [*Biomaterials* 35 (2014) 9802-10]'. *Biomaterials*. 2014 Jan;38:109.
- 160) Kameishi S, Sugiyama H, Yamato M, Sado Y, Namiki H, Kato T, Okano T. Remodeling of epithelial cells and basement membranes in a corneal deficiency model with long-term follow-up. *Lab Invest*. 2014 Dec 22.
- 161) Tanaka N, Ota H, Fukumori K, Miyake J, Yamato M, Okano T. Micro-patterned cell-sheets fabricated with stamping-force-controlled micro-contact printing. *Biomaterials*. 2014 Dec;35(37):9802-10.
- 162) Sasaki R, Matsumine H, Watanabe Y, Yamato M, Ando T. Surgical procedure of extracting teeth for obtaining dental pulp for regenerative medicine in swine. *Lab Anim*. 2014 Dec 1.
- 163) Kobayashi S, Kanai N, Ohki T, Takagi R, Yamaguchi N, Isomoto H, Kasai Y, Hosoi T, Nakao K, Eguchi S, Yamamoto M, Yamato M, Okano T. Prevention of esophageal strictures after endoscopic submucosal dissection. *World J Gastroenterol*. 2014 Nov

- 7;20(41):15098-109.
- 164) Takagi R, Yamato M, Okano T. [Regenerative medicine by cell sheet technology: the regeneration for stratified epithelial tissues]. *Arerugi*. 2014 Nov;63(9):1223-8. Japanese.
- 165) Yoshida T, Iwata T, Takai Y, Birchmeier W, Yamato M, Okano T. Afadin requirement for cytokine expressions in keratinocytes during chemically induced inflammation in mice. *Genes Cells*. 2014 Nov;19(11):842-52.
- 166) Kobayashi J, Hayashi M, Ohno T, Nishi M, Arisaka Y, Matsubara Y, Kakidachi H, Akiyama Y, Yamato M, Horii A, Okano T. Surface design of antibody-immobilized thermoresponsive cell culture dishes for recovering intact cells by low-temperature treatment. *J Biomed Mater Res A*. 2014 Nov;102(11):3883-93.
- 167) Akimoto J, Arauchi A, Nakayama M, Kanaya R, Iwase Y, Takagi S, Yamato M, Okano T. Facile cell sheet manipulation and transplantation by using in situ gelation method. *J Biomed Mater Res B Appl Biomater*. 2014 Nov;102(8):1659-68.
- 168) Sasaki R, Matsumine H, Watanabe Y, Takeuchi Y, Yamato M, Okano T, Miyata M, Ando T. Electrophysiologic and functional evaluations of regenerated facial nerve defects with a tube containing dental pulp cells in rats. *Plast Reconstr Surg*. 2014 Nov;134(5):970-8.
- 169) Sasaki R, Matsumine H, Watanabe Y, Yamato M, Ando T. Surgical anatomy of the hypoglossal nerve for facial nerve reconstruction research in Swine. *J Reconstr Microsurg*. 2014 Oct;30(8):585-8.
- 170) Matsumine H, Takeuchi Y, Sasaki R, Kazama T, Kano K, Matsumoto T, Sakurai H, Miyata M, Yamato M. Adipocyte-derived and dedifferentiated fat cells promoting facial nerve regeneration in a rat model. *Plast Reconstr Surg*. 2014 Oct;134(4):686-97.
- 171) Matsumine H, Sasaki R, Takeuchi Y, Watanabe Y, Niimi Y, Sakurai H, Miyata M, Yamato M. Unilateral Multiple Facial Nerve Branch Reconstruction Using "End-to-side Loop Graft" Supercharged by Hypoglossal Nerve. *Plast Reconstr Surg Glob Open*. 2014 Nov 7;2(10):e240.
- 172) Kumashiro Y, Ishihara J, Umemoto T, Itoga K, Kobayashi J, Shimizu T, Yamato M, Okano T. Stripe-Patterned Thermo-responsive Cell Culture Dish for Cell Separation without Cell Labeling. *Small*. 2014 Sep 19.
- 173) Ohki T, Yamato M, Ota M, Takagi R, Kondo M, Kanai N, Okano T, Yamamoto M. Application of regenerative medical technology using tissue-engineered cell sheets for endoscopic submucosal dissection of esophageal neoplasms. *Dig Endosc*. 2014 Sep 2.
- 174) Suzuki R, Aruga A, Kobayashi H, Yamato M, Yamamoto M. Development of a novel in vivo cancer model using cell sheet engineering. *Anticancer Res*. 2014 Sep;34(9):4747-54.
- 175) Takahashi H, Shimizu T, Nakayama M, Yamato M, Okano T. Anisotropic Cellular Network Formation in Engineered Muscle Tissue through the Self-Organization of Neurons and Endothelial Cells. *Adv Healthc*

- Mater. 2014 Aug 21. doi
- 176) Akiyama Y, Kikuchi A, Yamato M, Okano T. Accelerated cell-sheet recovery from a surface successively grafted with polyacrylamide and poly(N-isopropylacrylamide). *Acta Biomater.* 2014 Aug;10(8):3398-408.
- 177) Kumashiro Y, Matsunaga T, Muraoka M, Tanaka N, Itoga K, Kobayashi J, Tomiyama Y, Kuroda M, Shimizu T, Hashimoto I, Umemura K, Yamato M, Okano T. Rate control of cell sheet recovery by incorporating hydrophilic pattern in thermoresponsive cell culture dish. *J Biomed Mater Res A.* 2014 Aug;102(8):2849-56.
- 178) Sugiyama H, Yamato M, Nishida K, Okano T. Evidence of the survival of ectopically transplanted oral mucosal epithelial stem cells after repeated wounding of cornea. *Mol Ther.* 2014 Aug;22(8):1544-55.
- 179) Owaki T, Shimizu T, Yamato M, Okano T. Cell sheet engineering for regenerative medicine: current challenges and strategies. *Biotechnol J.* 2014 Jul;9(7):904-14.
- 180) Enoki Y, Sato T, Tanaka S, Iwata T, Usui M, Takeda S, Kokabu S, Matsumoto M, Okubo M, Nakashima K, Yamato M, Okano T, Fukuda T, Chida D, Imai Y, Yasuda H, Nishihara T, Akita M, Oda H, Okazaki Y, Suda T, Yoda T. Netrin-4 derived from murine vascular endothelial cells inhibits osteoclast differentiation in vitro and prevents bone loss in vivo. *FEBS Lett.* 2014 Jun 27;588(14):2262-9.
- 181) Kondo M, Yamato M, Takagi R, Murakami D, Namiki H, Okano T. Significantly different proliferative potential of oral mucosal epithelial cells between six animal species. *J Biomed Mater Res A.* 2014 Jun;102(6):1829-37.
- 182) Watanabe Y, Sasaki R, Matsumine H, Yamato M, Okano T. Undifferentiated and differentiated adipose-derived stem cells improve nerve regeneration in a rat model of facial nerve defect. *J Tissue Eng Regen Med.* 2014 Jun 1.
- 183) Matsumine H, Sasaki R, Yamato M, Okano T, Sakurai H. A polylactic acid non-woven nerve conduit for facial nerve regeneration in rats. *J Tissue Eng Regen Med.* 2014 Jun;8(6):454-62.
- 184) Pirraco RP, Iwata T, Yoshida T, Marques AP, Yamato M, Reis RL, Okano T. Endothelial cells enhance the in vivo bone-forming ability of osteogenic cell sheets. *Lab Invest.* 2014 Jun;94(6):663-73.
- 185) Matsumine H, Sasaki R, Tabata Y, Matsui M, Yamato M, Okano T, Sakurai H. Facial nerve regeneration using basic fibroblast growth factor-impregnated gelatin microspheres in a rat model. *J Tissue Eng Regen Med.* 2014 Apr 16.
- 186) Iwayama D, Yamato M, Tsubokura T, Takahashi M, Okano T. Cell/tissue processing information system for regenerative medicine. *J Tissue Eng Regen Med.* 2014 Apr 3.
- 187) Suphanantachat S, Iwata T, Ishihara J, Yamato M, Okano T, Izumi Y. A role for c-Kit in the maintenance of undifferentiated human mesenchymal stromal cells. *Biomaterials.* 2014 Apr;35(11):3618-26.
- 188) Ohki T, Yamato M, Okano T, Yamamoto M. Regenerative medicine: tissue-engineered cell